ArticleBMC cancer2015
No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses.European journal of medical research · 2023Pooled it
- Metformin and thyroid carcinoma incidence and prognosis: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Metabolic Reprogramming in Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Insulin Resistance: The Increased Risk of Cancers.Current oncology (Toronto, Ont.) · 2024Review
- Article
- Epidemiology of Thyroid Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- The association of obesity with thyroid carcinoma risk.Cancer medicine · 2022Review
- The AsSociation Between Type 2 Diabetes Mellitus, Hypothyroidism, and Thyroid Cancer.Acta clinica Croatica · 2020Article
- The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.Journal of molecular endocrinology · 2019Review
- Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.BMC cancer · 2018Article
- Metformin affects thyroid function in male rats.Oncotarget · 2017Article
- Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?Drug safety · 2017Review
- Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?Frontiers in endocrinology · 2017Review
- Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines.Journal of Cancer · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUse of metformin has been associated with a decreased cancer risk. We aimed to explore whether use of metformin or other antidiabetic drugs is associated with a decreased risk for thyroid cancer.
methodsWe conducted a case-control analysis (1995 to 2014) using the U.K.-based Clinical Practice Research Datalink (CPRD). Cases had a first-time diagnosis of thyroid cancer, six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the database prior to the index date. We assessed odds ratios (ORs) with 95 % confidence intervals (95 % CI), adjusted for body mass index (BMI), smoking, and diabetes mellitus.
resultsIn 1229 cases and 7374 matched controls, the risk of thyroid cancer associated with ever use of metformin yielded an adjusted OR of 1.48, 95 % CI 0.86-2.54. The relative risk estimate was highest in long-term (≥30 prescriptions) users of metformin (adjusted OR 1.83, 95 % CI 0.92-3.65), based on a limited number of 26 exposed cases. No such association was found in users of sulfonylurea, insulin, or thiazolidinediones (TZD). Neither a diabetes diagnosis (adjusted OR 1.17, 95 % CI 0.89-1.54), nor diabetes duration >8 years (adjusted OR 1.22, 95 % CI 0.60-2.51) altered the risk of thyroid cancer.
conclusionIn our observational study with limited statistical power, neither use of metformin nor of other antidiabetic drugs were associated with a decreased risk of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.